Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
HSV Testing Market Size & Share 2026-2035
Report ID: GMI14582
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
HSV Testing Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
HSV Testing Market Size
The HSV testing market was valued at USD 875 million in 2025, is projected to reach USD 944 million in 2026, and is forecast to expand at an 8.0% CAGR (2026-2035), reaching USD 1.89 billion by 2035.
Hsv Testing Market Key Takeaways
Market Leader: Roche led with over 18% market share in 2025.
Leading Players: Top 5 players in this market include Roche, Abbott, Hologic, Danaher, BD, which collectively held a market share of 58% in 2025.
The HSV testing market encompasses diagnostic products used to detect and differentiate HSV-1 and HSV-2 across laboratory, hospital, near-patient, and home-collection settings. Growth reflects recurring clinical need, broader STI surveillance activity, and a revenue mix increasingly shaped by molecular consumables and decentralized testing access.
GMI Analyst View
Our engagements with diagnostics industry executives and clinical procurement specialists indicate that the HSV testing market was estimated at USD 704 million in 2022, confirming a consistent multi-year demand build-up that predates the base year and validates the momentum carried into the current forecast model.
HSV Testing Market Trends, Growth Drivers & GMI Forecast Outlook
Disease burden, public-health procurement, and molecular platform deployment are expanding the addressable testing base, while affordability and laboratory readiness determine how quickly demand converts into revenue. The outlook favors settings that can combine type-specific clinical utility with accessible collection, workflow, and reimbursement models.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Genital herpes creates recurring testing occasions rather than a one-time diagnostic event. New infections and recurrent symptoms continually replenish the pool of patients requiring type differentiation, clinical counseling, or confirmatory testing. WHO estimates that genital herpes causes 42 million new infections annually and imposes an estimated USD 35 billion annual economic burden through direct healthcare costs and productivity loss [1]World Health Organization. "Over 1 in 5 Adults Worldwide Has a Genital Herpes Infection." who.int. Antenatal and neonatal care add high-acuity testing needs, particularly where clinicians require rapid differentiation from blood, swab, or CSF specimens.
National STI strategies matter commercially because they influence laboratory investment, procurement cycles, surveillance design, and the availability of testing pathways. WHO reported that 95 countries had integrated dual rapid HIV/syphilis testing into national policy, establishing an operational precedent for scaled rapid-test procurement and broader STI panel deployment [2]World Health Organization. "WHO Expands Guidance on Sexually Transmitted Infections and Reviews Country Progress on Policy Implementation." who.int. For HSV suppliers, the opportunity is strongest where public programs link laboratory modernization with sexual-health service expansion.
Regulatory clarity also supports technology adoption in specialist settings. The U.S. Food and Drug Administration's class II classification action for HSV nucleic acid-based assays for central nervous system infections reduces the regulatory burden for qualifying CSF-focused molecular products [3]U.S. Food and Drug Administration, Federal Register. "Classification of the Herpes Simplex Virus Nucleic Acid-Based Assay for Central Nervous System Infections." federalregister.gov. This expands the commercial relevance of high-sensitivity testing in neurology, emergency, and infectious-disease workflows.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Molecular testing economics create a practical access divide. Medicare's average payment for PCR-based HSV nucleic-acid detection was USD 34.35 per test in 2023, limiting the room for smaller laboratories to fund platform expansion where throughput is uncertain [5]PlainProcedure. "Detection Test by Nucleic Acid for Herpes Simplex Virus, Amplified Probe Technique (87529) Cost." plainprocedure.com. In markets without reliable reimbursement, providers and patients may instead select lower-cost serological formats despite their narrower clinical utility for active infection diagnosis.
Laboratory gaps are not simply a matter of disease awareness. Cold-chain requirements, capital equipment needs, maintenance capability, and specialized personnel all affect whether molecular assays can be deployed reliably. These constraints are especially consequential in settings where public-health demand is substantial but decentralized facilities lack the infrastructure needed to sustain advanced testing workflows.
Guideline caution regarding asymptomatic HSV-2 screening also restricts routine test ordering. False-positive risk and confirmatory-testing requirements can make broad opportunistic screening clinically unattractive, concentrating demand in symptomatic care, partner testing, antenatal evaluation, and targeted sexual-health services.
GMI Analyst View
We view the market's central tension as the gap between expanding clinical recognition and uneven diagnostic affordability. Molecular and near-patient formats carry the strongest strategic upside, but their adoption depends on whether suppliers can align reagent economics, reimbursement support, and workflow simplicity with the needs of cost-sensitive care settings.
HSV Testing Market Segment Analysis
By Product
Reagents & kits generated USD 569 million in 2025 and are projected to account for 70.0% of HSV testing market revenue in 2035. Their position reflects the recurring consumable requirements of molecular amplification, immunoassay, quality-control, and rapid-testing workflows.
The product mix is shifting toward recurring test-use revenue as installed molecular platforms process a greater share of samples. Suppliers with broad reagent menus and dependable supply capability are positioned to benefit more consistently than those reliant on episodic instrument placements.
Instruments accounted for 35.0% of HSV testing market revenue in 2025 and are projected to generate USD 566 million in 2035. Demand includes automated molecular systems, immunoassay analyzers, and decentralized readers used across hospital, laboratory, and near-patient environments.
Instrument demand remains important where laboratory capacity is being added or upgraded, but purchase timing is tied to capital cycles. Commercial success increasingly depends on placing systems that create durable downstream reagent demand rather than on equipment revenue alone.
By Type
HSV-1/HSV-2 Combined assays generated USD 455 million in 2025 and are projected to account for 50.0% of HSV testing market revenue in 2035. Combined assays address the clinical need for type differentiation in counseling, transmission assessment, and treatment-pathway decisions.
Their continued leadership reflects the value of consolidating testing into one workflow. Multiplex capability is particularly important to laboratories seeking to preserve throughput while providing clinically differentiated results.
HSV-2 tests accounted for 26.0% of HSV testing market revenue in 2025 and are projected to generate USD 566 million in 2035. Demand is supported by HSV-2's role in recurrent genital herpes management and targeted sexual-health testing.
The segment benefits from increasing emphasis on type-specific clinical interpretation and integration into STI-testing protocols. Its commercial potential is strongest in settings where sexual-health programs can support confirmatory testing and guideline-concordant ordering.
HSV-1 tests generated USD 193 million in 2025 and are projected to expand at a 7.0% CAGR (2026-2035). Their use is concentrated in oral-labial surveillance, neonatal workups, and high-acuity neurological applications such as suspected HSV encephalitis.
Clinical demand for rapid, sensitive confirmation in hospital-based care supports this segment. The availability of molecular assays validated for high-consequence specimen types reinforces its role within specialist diagnostic pathways.
By Test Type
Serological testing generated USD 481 million in 2025 and is projected to account for 48.0% of HSV testing market revenue in 2035. It remains widely used in outpatient, antenatal, surveillance, and cost-sensitive testing pathways.
Its future role is shaped by accessibility rather than by clinical superiority for active disease. Serology retains a broad installed base, although guideline restrictions and molecular substitution limit its share progression in more developed diagnostic markets.
Direct detection accounted for 30.0% of HSV testing market revenue in 2025 and is projected to generate USD 604 million in 2035. PCR-based assays from swab, CSF, blood, and urine specimens are central to active-infection diagnosis.
The segment benefits from clinical preference for lesion-site and high-sensitivity testing when treatment decisions require rapid confirmation. Growing automation in hospitals and reference laboratories supports direct detection's expanding revenue contribution.
POC Testing generated USD 131 million in 2025 and is projected to expand at an 11.2% CAGR (2026-2035). The category includes rapid formats and cartridge-based molecular systems used in sexual-health clinics, community care, and emergency settings.
Near-patient testing addresses the operational cost of delayed diagnosis by allowing clinicians to make treatment and counseling decisions within the same care encounter. Its growth depends on balancing analytical performance with price, workflow simplicity, and decentralized quality assurance.
By Sample Type
Blood-based testing generated USD 411 million in 2025 and is projected to retain 45.0% of sample-type revenue in 2035. Its scale reflects the continued use of blood-based serological workflows in outpatient, surveillance, and antenatal settings.
Blood remains a practical matrix where antibody testing is clinically appropriate, but its relative position is moderated by the expansion of direct-detection workflows that rely on lesion-site and noninvasive specimens.
Swabs accounted for 33.0% of HSV testing market revenue in 2025 and are projected to generate USD 623 million in 2035. Swab specimens are integral to direct molecular detection in symptomatic anogenital, oral, and cutaneous presentations.
The sample type benefits from clinician preference for collecting material from the site of active infection. As molecular capacity extends into more care settings, swab-based workflows are likely to remain central to clinically actionable HSV diagnosis.
Urine accounted for 12.0% of HSV testing market revenue in 2025 and is projected to expand at a 10.4% CAGR (2026-2035). Its growth is linked to demand for noninvasive collection in clinical, telehealth-supported, and home-initiated testing pathways.
Patient convenience gives urine testing a differentiated role where collection friction can discourage testing. The format is particularly relevant to consumer-accessible services that require scalable collection and laboratory referral models.
CSF-based testing generated USD 70 million in 2025 and is projected to reach USD 132 million in 2035. This specialized segment serves suspected HSV encephalitis, meningitis, and other central nervous system presentations that require rapid molecular confirmation.
Although smaller than blood or swab testing, CSF applications carry high clinical urgency. Regulatory clarity and the expanding use of molecular neurology protocols strengthen the relevance of validated assays in hospital and intensive-care workflows.
By End Use
Hospitals generated USD 394 million in 2025 and are projected to account for 42.0% of HSV testing market revenue in 2035. They remain the principal channel for inpatient workups, antenatal care, emergency testing, neonatal evaluation, and immunocompromised-patient management.
Hospital purchasing favors platforms that can support broad test menus, reliable turnaround, and specialist specimen handling. This makes the channel strategically important for suppliers with integrated molecular and immunoassay capabilities.
Diagnostic Laboratories accounted for 30.0% of HSV testing market revenue in 2025 and are projected to generate USD 548 million in 2035. The channel processes outpatient, reference, hospital-affiliated, and telehealth-referred samples at scale.
Laboratory consolidation supports high-throughput molecular workflows and reinforces the importance of automation, connectivity, and predictable reagent supply. Partnerships with digital-health and home-collection providers can further increase referral volumes.
Home Care/Self-Testing accounted for 13.0% of HSV testing market revenue in 2025 and is projected to expand at a 10.2% CAGR (2026-2035). Growth reflects increasing consumer acceptance of home-initiated STI testing and laboratory-linked specimen collection.
This channel can expand access where privacy, convenience, or appointment availability limit clinic-based testing. Its commercial development depends on clear consumer guidance, dependable collection logistics, and appropriate clinical follow-up for positive or inconclusive results.
GMI Analyst View
We see the segmentation pattern as evidence of a broader shift from stand-alone diagnostic transactions toward recurring, distributed testing ecosystems. Consumables, combined assays, direct detection, and patient-proximate channels each reinforce the strategic value of suppliers that can connect clinical sensitivity with convenient access and repeatable workflow economics.
HSV Testing Market Regional Analysis
North America HSV Testing Market Analysis
North America accounted for 35.0% of HSV testing market revenue in 2025 and is projected to generate USD 519 million in 2035. The HSV Testing Market in the region is supported by established reimbursement structures, mature hospital and reference-laboratory networks, and broad access to molecular and immunoassay platforms.
Market maturity constrains incremental volume growth, but the region remains a critical proving ground for advanced molecular workflows, near-patient formats, and consumer-linked testing models. Supplier differentiation depends on menu breadth, automation, and integration with established clinical pathways.
United States (U.S.)
The United States generated USD 268 million in 2025 and is projected to reach USD 447 million in 2035. Institutional procurement, laboratory-to-patient ordering models, and STI surveillance programs support demand across hospital, reference-laboratory, and consumer-access channels.
The market's commercial depth favors suppliers able to serve both high-throughput centralized laboratories and decentralized care sites. Reimbursement discipline and guideline-concordant ordering remain important determinants of test mix.
Canada
Canada accounted for 12.4% of North American revenue in 2025 and is projected to expand at a 6.6% CAGR (2026-2035). Provincial public-health laboratories and sexual-health clinics provide the principal institutional testing infrastructure.
Further demand is likely to be shaped by the pace of molecular adoption across provincial networks and by the ability of testing services to expand access beyond specialist urban centers.
Europe HSV Testing Market Analysis
Europe generated USD 210 million in 2025 and is projected to account for 20.1% of HSV testing market revenue in 2035. The HSV Testing Market in Europe is shaped by varied national health-service structures, public procurement models, and differing levels of private laboratory participation.
Molecular adoption continues to deepen, although country-level reimbursement structures and clinical guidance create uneven testing patterns. Suppliers need localized channel and tender strategies rather than a single regional commercial approach.
Germany
Germany generated USD 48 million in 2025 and is projected to account for 23.7% of European revenue in 2035. Its hospital and laboratory infrastructure supports demand for automated molecular and immunoassay testing.
The country's established diagnostics base favors integrated platforms that can fit routine laboratory workflows while supporting type-specific testing in specialist clinical services.
United Kingdom (UK)
The United Kingdom accounted for 19.0% of European revenue in 2025 and is projected to generate USD 74 million in 2035. Sexual-health clinic capacity and general-practitioner referral pathways underpin institutional demand.
The NHS-oriented service model makes procurement efficiency, patient access, and turnaround performance central to supplier positioning, particularly as home-collection services supplement clinic-based testing.
France
France generated USD 35 million in 2025 and is projected to expand at a 6.1% CAGR (2026-2035). Public reimbursement for molecular STI diagnostics supports a stable institutional demand base.
Future growth is likely to remain linked to clinical adoption within hospital and laboratory networks rather than broad asymptomatic screening expansion.
Asia Pacific HSV Testing Market Analysis
Asia Pacific generated USD 245 million in 2025 and is projected to expand at an 11.1% CAGR (2026-2035). The HSV Testing Market in Asia Pacific combines a large underaddressed disease burden with increasing laboratory investment, expanding private diagnostic capacity, and accelerating adoption of POC technologies.
The region's opportunity is substantial but operationally heterogeneous. Success depends on pricing, channel design, regulatory engagement, and products that can function across both sophisticated urban laboratories and resource-constrained decentralized settings.
China
China generated USD 82 million in 2025 and is projected to account for 36.0% of Asia Pacific revenue in 2035. Expanding hospital molecular capacity and growing demand for premium diagnostics in major cities support its regional importance.
National prevention initiatives and private-sector expansion create a sizable platform opportunity, although suppliers must align offerings with local procurement, registration, and distribution requirements.
India
India accounted for 18.4% of Asia Pacific revenue in 2025 and is projected to expand at a 12.6% CAGR (2026-2035). Demand is supported by large unmet STI diagnostic needs, laboratory-network development, and expanding private diagnostic chains.
The market favors solutions that combine affordability with operational resilience. Rapid and molecular formats can coexist as care providers balance clinical performance against access and patient affordability.
Japan
Japan generated USD 52 million in 2025 and is projected to reach USD 132 million in 2035. Hospital virology and infectious-disease services underpin demand for molecular testing, particularly where HSV complications require high-confidence diagnosis.
Its established healthcare infrastructure supports adoption of sophisticated workflows, while demographic and clinical-complexity considerations reinforce the value of timely testing.
South Korea
South Korea generated USD 28 million in 2025 and is projected to reach USD 70 million in 2035. Private laboratory expansion, STI surveillance activity, and local molecular-diagnostics capability support demand.
The country also has strategic relevance as an innovation and manufacturing node, creating opportunities for both domestic adoption and broader regional product development.
Latin America HSV Testing Market Analysis
Latin America accounted for 7.0% of HSV testing market revenue in 2025 and is projected to generate USD 158 million in 2035. The HSV Testing Market in Latin America is supported by public-health laboratory programs, private diagnostic-network expansion, and increasing demand for STI services in major urban areas.
Testing access remains uneven, making price, procurement execution, and decentralized service models important competitive variables. The region's growth potential is closely tied to the ability to expand dependable laboratory capacity beyond core metropolitan markets.
Brazil
Brazil accounted for 45.9% of Latin American revenue in 2025 and is projected to expand at a 9.8% CAGR (2026-2035). Its public laboratory infrastructure and large urban private-diagnostics market establish it as the region's principal commercial entry point.
Scale gives suppliers the opportunity to build meaningful institutional volume, but success requires engagement with both public procurement channels and fragmented private laboratory networks.
Middle East & Africa HSV Testing Market Analysis
Middle East & Africa generated USD 53 million in 2025 and is projected to expand at a 9.5% CAGR (2026-2035). The HSV Testing Market in Middle East & Africa is characterized by strong investment potential in GCC healthcare systems alongside persistent laboratory-capacity gaps across many lower-resource markets.
Growth depends on how effectively healthcare investment translates into routine diagnostic availability. Suppliers that can pair reliable technology with training, distribution support, and affordable operating models are better positioned to convert unmet need into sustained demand.
Saudi Arabia
Saudi Arabia generated USD 14 million in 2025 and is projected to reach USD 38 million in 2035. Healthcare investment, hospital laboratory expansion, and private-sector diagnostics development support its position as a leading GCC market.
The country offers a concentrated institutional opportunity, with demand shaped by laboratory modernization and the ability of providers to integrate advanced testing into broader sexual-health and infectious-disease services.
GMI Analyst View
We interpret the regional outlook as a shift in the market's center of gravity toward faster-developing testing ecosystems. Mature regions remain commercially important for advanced platform adoption, while Asia Pacific, Latin America, and Middle East & Africa offer the greater expansion opportunity for companies that can localize pricing, service, regulatory, and procurement models.
HSV Testing Market Share & Competitive Landscape
The HSV testing market is moderately concentrated, with Roche, Abbott, Hologic, Danaher, and BD collectively accounting for 58% of market revenue in 2025. HSV testing market share is therefore shaped by the installed base of molecular and immunoassay platforms, menu breadth, laboratory relationships, and the ability to support both centralized and decentralized testing environments.
Roche held an 18% market share in 2025. Its position is supported by the cobas molecular platform family, integrated serological testing capability, and a broad laboratory footprint that serves high-throughput hospital and reference-laboratory customers. Its development of near-patient lesion-panel capabilities indicates an effort to extend HSV testing beyond centralized workflows.
Abbott held a 14% market share in 2025. Abbott's Alinity m and ARCHITECT platforms allow it to address molecular and immunoassay demand across reference laboratories and hospital settings. Its automated workflow capabilities are particularly relevant to high-volume STI programs requiring efficient processing of lesion specimens.
Hologic held a 10% market share in 2025. The Aptima HSV 1 & 2 assay on the Panther platform positions the company within integrated sexual-health testing workflows. The ability to process HSV alongside other STI targets supports laboratory efficiency and reinforces Hologic's role in consolidated testing programs.
Danaher held a 9% market share in 2025, with Cepheid's GeneXpert platform providing access to both institutional and decentralized testing channels. Its sample-to-answer molecular workflow is suited to hospitals, community health centers, and public-health laboratory networks seeking faster operational deployment.
BD held a 7% market share in 2025. BD MAX and associated molecular reagents support HSV testing in hospital microbiology and molecular laboratories, where the platform's flexibility and installed base contribute to recurring reagent demand.
Recent Industry Developments
Seegene USA received FDA Emergency Use Authorization in July 2026 for the Allplex HSV-1&2/VZV/MPXV assay, a multiplex PCR test designed to differentiate HSV-1, HSV-2, varicella-zoster virus, and monkeypox virus from a single lesion specimen [6]Seegene. "Seegene USA Receives FDA Emergency Use Authorization for Multiplex PCR Assay, Advancing Differential Diagnosis of HSV-1&2, VZV, and Monkeypox Virus for Ulcerative Skin Lesions." prnewswire.com. The development broadens the clinical utility of HSV molecular testing in dermatology, emergency, and sexual-health settings where ulcerative lesions require differential diagnosis.
Cepheid announced a third-generation GeneXpert molecular diagnostic system in July 2026, designed to expand PCR capabilities while maintaining backward compatibility with its existing Xpert assay menu [7]Cepheid. "Cepheid to Unveil Third-Generation GeneXpert System at ADLM 2026, Advancing Molecular Diagnostic Capabilities." prnewswire.com. The development reinforces Danaher's installed-base strategy in decentralized molecular testing and supports continuity for laboratories using GeneXpert workflows.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →